ESMO® 2026 Highlights: Presenter Vignettes – Benjamin Garmezy

Dr. Benjamin Garmezy

Benjamin Garmezy

MD

Sarah Cannon Research Institute

2216O

Safety and efficacy of JNJ-6143, a first-in-class oral AR-targeted RIPTAC™ at the optimal dose for further development in patients with mCRPC/mAPMR, including high-risk molecular features